Angelo M. Carella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angelo M. Carella has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
A. Mussetti
Division of Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
1 shared publication- Alberto Fabbri
Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy
1 shared publication - Alessandro Pulsoni
Division of Hematology, Department of Translational and Precision Medicine, S.M. Goretti Hospital Sapienza University—Polo Pontino Latina Italy
1 shared publication - Andrea Gallamini
Onco‐Hematology, Centre Antoine‐Lacassagne Nice France
1 shared publication - Anna Marina Liberati
Università degli studi di Perugia, Azienda Ospedaliera Santa Maria, Terni, Italy
1 shared publication - Armando Santoro
Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano (Milan), Italy
1 shared publication
Latest Publications
- 30 July 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (10) , 2547-2556
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi
We investigated the feasibility and activity of an intensified dose-dense ABVD (dd-ABVD) regimen in patients with early-stage unfavorable Hodgkin lymphoma (HL). This prospective, multicenter, phase II study enrolled 96 patients with newly diagnosed, unfavorable stage I or II classical HL. The patients received four cycles of dd-ABVD followed by radiotherapy. Interim PET (PET-2) was mandatory after two courses. Primary endpoints were the evaluation of dd-ABVD feasibility and activity (incidence of PET-2 negativity). The feasibility endpoint was achieved with 48/52 (92.3%) patients receiving > 85% of the programmed dose. The mean dose intensity in the overall patient population (n = 96) was 93.7%, and the median duration of dd-ABVD was 85 days (range, 14–115) versus an expected duration of 84 days. PET-2 was available for 92/96 (95.8%) patients, of whom 79 were PET-2 negative (85.9%). In total, 90 (93.8%) patients showed complete response at the end of treatment. With a follow-up of 80.9 months (3.3–103.2), the median progression-free survival (PFS) and overall survival (OS) were not reached. At 84 months, PFS and OS rates were 88.4% and 95.7%, respectively. No evidence for a difference in PFS or OS was observed for PET-2-negative and PET-2-positive patients. Infections were documented in 8.3% and febrile neutropenia in 6.2% of cases. Four patients died: one had alveolitis at cycle 3, one death was unrelated to treatment, and two died from a secondary cancer. dd-ABVD is feasible and demonstrates activity in early-stage unfavorable HL. The predictive role of PET-2 positivity in early-stage unfavorable HL remains controversial. The study was registered in the EudraCT (reference number, 2011–003,191-36) and the ClinicalTrials.gov (reference number, NCT02247869) databases.
- 30 July 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (10) , 2547-2556
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi
We investigated the feasibility and activity of an intensified dose-dense ABVD (dd-ABVD) regimen in patients with early-stage unfavorable Hodgkin lymphoma (HL). This prospective, multicenter, phase II study enrolled 96 patients with newly diagnosed, unfavorable stage I or II classical HL. The patients received four cycles of dd-ABVD followed by radiotherapy. Interim PET (PET-2) was mandatory after two courses. Primary endpoints were the evaluation of dd-ABVD feasibility and activity (incidence of PET-2 negativity). The feasibility endpoint was achieved with 48/52 (92.3%) patients receiving > 85% of the programmed dose. The mean dose intensity in the overall patient population (n = 96) was 93.7%, and the median duration of dd-ABVD was 85 days (range, 14–115) versus an expected duration of 84 days. PET-2 was available for 92/96 (95.8%) patients, of whom 79 were PET-2 negative (85.9%). In total, 90 (93.8%) patients showed complete response at the end of treatment. With a follow-up of 80.9 months (3.3–103.2), the median progression-free survival (PFS) and overall survival (OS) were not reached. At 84 months, PFS and OS rates were 88.4% and 95.7%, respectively. No evidence for a difference in PFS or OS was observed for PET-2-negative and PET-2-positive patients. Infections were documented in 8.3% and febrile neutropenia in 6.2% of cases. Four patients died: one had alveolitis at cycle 3, one death was unrelated to treatment, and two died from a secondary cancer. dd-ABVD is feasible and demonstrates activity in early-stage unfavorable HL. The predictive role of PET-2 positivity in early-stage unfavorable HL remains controversial. The study was registered in the EudraCT (reference number, 2011–003,191-36) and the ClinicalTrials.gov (reference number, NCT02247869) databases.
- 3 June 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (6) , 928-930
Present results and future perspectives in optimizing chronic myeloid leukemia therapy
The presence of the Philadelphia chromosome and BCR/ABL1 fusion, combined with an elevated leukocyte count and other less specific clinical and hematological features, defines chronic myeloid leukemia (CML). In the last two decades, tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment
- 3 June 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (6) , 928-930
Present results and future perspectives in optimizing chronic myeloid leukemia therapy
The presence of the Philadelphia chromosome and BCR/ABL1 fusion, combined with an elevated leukocyte count and other less specific clinical and hematological features, defines chronic myeloid leukemia (CML). In the last two decades, tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment
- 25 May 2018
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (8) , 1301-1315
Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40–50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.
- 25 May 2018
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (8) , 1301-1315
Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40–50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.